Sun Pharma Secures US Market Access via Strategic ‘Most Favoured Nation’ Pricing Deal

In a major development for the Indian pharmaceutical sector, Sun Pharma, the country’s largest drug manufacturer, has entered into a landmark agreement with the US government to provide ‘Most Favoured Nation’ (MFN) pricing for its products under the US Medicaid program. This strategic move, finalized on August 31, serves as a proactive measure to mitigate the threat of steep tariffs on imported pharmaceutical goods.

A Playbook for Market Expansion

The agreement acts as a significant shield for Sun Pharma, successfully delaying the imposition of potential Section 232 tariffs on its innovative pharmaceutical products for over two years. The US government had previously signaled plans to impose a 100% duty on innovative, patented drug imports, with tariffs on generic medicines slated to climb to 100% by August 2028 and 200% the following year.

By opting for MFN pricing—a framework that guarantees the buyer the lowest price offered to any other developed nation—Sun Pharma has effectively secured its position in the world’s largest pharmaceutical market. Analysts view the deal as a masterclass in navigating geopolitical trade risks.

“The agreement is a politically astute decision that needed to be made, while it also removes the overhang of tariffs,” said Vishal Manchanda, an analyst at Systematix Group. “With the Organon deal, the company’s scale will increase significantly. There will be hardly any impact on earnings due to the price reductions.”

Strategic Shift to Specialty Medicines

The United States remains a cornerstone of Sun Pharma’s growth strategy, contributing approximately 27% of its global revenue. While the company initially established its reputation in the US through generics, it has been aggressively pivoting toward high-value specialty and innovative medicines. Currently, Sun Pharma holds a strong competitive position, ranking second by prescriptions in the US dermatology market, with further expansions planned in immunology, cutaneous oncology, and ophthalmology.

The company’s portfolio of innovative drugs in the US, currently valued at roughly $1 billion, is projected to surge to $3 billion following its acquisition of Organon.

Strengthening US Healthcare Infrastructure

Beyond pricing, Sun Pharma has committed to bolstering the American domestic supply chain. As part of the agreement, the company will contribute significant quantities of Active Pharmaceutical Ingredients (APIs)—specifically 71.4 tons of clindamycin and 6.8 tons of doxycycline—to the Strategic Active Pharmaceutical Ingredients Reserve (SAPIR). This initiative aims to reduce US reliance on foreign nations for critical antibiotics and ensure national preparedness.

Rick Ascroft, North America CEO of Sun Pharma, emphasized the company’s deep integration into the US ecosystem: “The United States is a key area of investment and expansion for Sun Pharma across clinical development, sales and marketing, and both API and finished products manufacturing.”

Broad Industry Impact

Sun Pharma is one of nine pharmaceutical giants that signed agreements at the White House on August 31, joining a collective effort to lower the costs of treatments for chronic and rare diseases, including Parkinson’s, hemophilia, glaucoma, and various cancers.

With this latest development, the number of pharmaceutical manufacturers holding MFN-style deals with the US government has risen to 26. These agreements now collectively cover approximately 89% of the branded drug market in the United States, signaling a new era of cooperation between global suppliers and the US administration to prioritize affordable patient access.

As the industry watches how this Sun Pharma deal evolves, it remains clear that the move has provided the company with both regulatory breathing room and a reinforced footing to continue its expansion in the West.